External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Immunology Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Nov 16 / Roche and Genentech
Evaluating the concordance between SRI-4 and BICLA in the EXPLORER and ATHOS trials in active systemic lupus erythematosus
This post hoc analysis of 2 systemic lupus erythematosus randomized controlled trials (EXPLORER [NCT00137969] and ATHOS [NCT02908100]) examined concordance in British Isles Lupus Assessment Group (BILAG)–based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI-4) outcome measures among participants receiving placebo and standard of care, and explored reasons for BICLA and SRI-4 discordance.
Immunology Systemic Lupus Erythematosus ACR-2024

Sign up or login to unlock the full suite of MEDICALLY features
Jun 14 / Roche and Genentech
Evaluating the concordance between SRI-4 and BICLA in the EXPLORER and ATHOS trials in active systemic lupus erythematosus
This post hoc analysis of 2 systemic lupus erythematosus randomized controlled trials (EXPLORER [NCT00137969] and ATHOS [NCT02908100]) examined concordance in British Isles Lupus Assessment Group (BILAG)–based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI-4) outcome measures among participants receiving placebo and standard of care (SOC) and explored reasons for BICLA and SRI-4 discordance.
Immunology Systemic Lupus Erythematosus EULAR-2024

Sign up or login to unlock the full suite of MEDICALLY features
Nov 14 / Roche and Genentech
Patient-Reported Outcomes in Patients With Lupus Nephritis: A Post Hoc Analysis of Control Arm Data From Two Completed Phase III Randomized Clinical Trials
This post hoc descriptive analysis aimed to characterize the impact of kidney function on health-related quality of life (HRQOL) in patients with lupus nephritis (LN) who received standard-of-care (SOC) therapy while enrolled in the control arm of the global Phase III randomized controlled trials: LUNAR (NCT00282347) and BELONG (NCT00626197).
Immunology Systemic Lupus Erythematosus ACR-2023
Upcoming Congresses
Access to Roche and Genentech's medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.